Boulogne-Billancourt, France, October 27, 2010 -- Porsolt is pleased to announce the appointment of Dr. David Pushett as Director of Global Business Development, reflecting the company’s expansion into new and emerging markets, servicing the Pharmaceutical and Biotech industries worldwide.
Dr. Pushett brings more than 15 years of biotech research and business experience to Porsolt, including an extensive knowledge of the CRO industry, contract negotiations, strategic planning, and technology assessment. Dr. Pushett will play a key role in supporting Porsolt’s international business development team and identifying new and expanding markets.
“We are extremely excited about David’s appointment. His extensive knowledge and experience in the industry will strengthen Porsolt’s business expansion strategy,” said Dr. Mark Duxon, CEO. “This appointment continues Porsolt’s drive to provide its clients with experienced industry personnel to support their projects.”
Prior to this appointment, Dr. David Pushett was Vice President of Business Development at PsychoGenics Inc, a preclinical CRO. Prior to this he served as Chief Operations Officer of MindGenix, a CRO focused on preclinical testing services for Alzheimer’s Disease. Dr. Pushett received his Ph.D. from Monash University, Australia.
“I am delighted to be part of this exciting organization”, said Dr David Pushett, Director of Global Business Development. “I have joined Porsolt at an exciting time and look forward to working with the team to expand the company’s presence in the global pharmaceutical and biotech markets.”
About Porsolt SAS
Porsolt is a long established preclinical CRO, having started operations in 1984 under the name ITEM-Labo. Porsolt has obtained an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, and metabolic and eating disorders. Porsolt also offers services for safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration in full compliance with GLP (ICH S7), including full assessment of arrhythmogenic risk and abuse and dependence liability. Porsolt is located in France with facilities in Paris and Laval and in the US with facilities in San Antonio, Texas.
For additional information about the organization, please visit www.porsolt.com or email us at contact@porsolt.com
